The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1
|
作者：
Chen, Xi [1 ]
Wei, Xinyu [1 ]
Yao, Peizhuo [1 ]
Liu, Yanbin [1 ]
Guan, Haitao [2 ]
Kang, Huafeng [2 ]
Liu, Di [2 ]
Diao, Yan [2 ]
Ma, Xiaobin [2 ]
Min, Weili [2 ]
Shan, Changyou [2 ]
Zhao, Yang [2 ]
Zhao, Fang [2 ]
Chen, Yuanyuan [3 ]
Xiao, Dong [4 ]
She, Qing [3 ]
Liu, Youhuai [3 ]
Zhang, Yinbin [2 ]
Zhang, Shuqun [2 ]
机构：
[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China
[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China
来源：
CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期
关键词：
1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;
D O I：
10.1016/j.clbc.2024.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 202
页数：8
相关论文
共 50 条
  • [41] Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, open-label, single-arm phase II study
    Long, B.
    Zhou, H.
    Wei, D.
    Yang, T.
    Chai, N.
    Yu, Z.
    Yang, H.
    Guan, X.
    Zhang, W.
    Chen, S.
    Zhou, L.
    Jiang, X.
    Shi, W.
    Huang, Z.
    Zhu, J.
    Luo, C.
    Mao, J.
    Dong, C.
    Jiang, Z.
    Zhao, X.
    Zhao, D.
    Jiao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S70 - S71
  • [42] Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study
    He, Min
    Hao, Shuang
    Ma, LinXiaoxi
    Xiu, BingQiu
    Yang, BenLong
    Wang, ZeHao
    Xue, JingYan
    Chi, YaYun
    Xiong, Min
    Chen, Jiajian
    Huang, XiaoYan
    Liu, XiYu
    Wu, SongYang
    Xiao, Qin
    Huang, Yan
    Shui, RuoHong
    Cao, AYong
    Li, JunJie
    Di, GenHong
    Yang, WenTao
    Hu, Xin
    Liu, GuangYu
    Yu, KeDa
    Jiang, YiZhou
    Wang, ZhongHua
    Shao, ZhiMing
    Wu, Jiong
    ECLINICALMEDICINE, 2024, 74
  • [43] Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial
    Jiao, Dechuang
    Qiao, Jianghua
    Wang, Chengzheng
    Li, Juntao
    Sun, Xianfu
    Lu, Zhenduo
    Zhang, Chongjian
    Li, Lianfang
    Yan, Min
    Feng, Yueqing
    Zhou, Yong
    Deng, Miao
    Liu, Xinlan
    Ma, Mingde
    Jia, Haiquan
    Xia, Qingxin
    Chen, Xiuchun
    Liu, Zhenzhen
    CANCER RESEARCH, 2024, 84 (09)
  • [44] MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results
    Kuemmel, S.
    Abraham, J.
    Martin, M.
    Crepelle-Flechais, A.
    Swat, A.
    Nueesch, E.
    Shing, M.
    Tondini, C. A.
    CANCER RESEARCH, 2017, 77
  • [45] Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.
    Xu, Yiying
    Wu, Xue
    Yang, Chenghui
    Xia, Erjie
    Wang, Yinghao
    Dai, Xuanxuan
    Liu, Haiguang
    Chen, Yizuo
    Wang, Wenqian
    Guo, Guilong
    Wu, Weili
    Li, Xiaoyang
    Wang, Ouchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
    Nabholtz, J-M
    Weber, B.
    Gligorov, J.
    Mouret-Reynier, M-A
    Tredan, O.
    Vanlemmens, L.
    Petit, T.
    Mayer, F.
    Van Praagh-Doreau, I
    Dubray-Longeras, P.
    Nayi, B.
    Ferriere, J-P
    Jouannaud, C.
    Devaud, H.
    Tubiana-Mathieu, N.
    Abrial, C.
    Kwiatkowski, F.
    Planchat, E.
    Chalabi, N.
    Penault-Llorca, F.
    Chollet, P.
    CANCER RESEARCH, 2011, 71
  • [47] Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
    Tanimura, Keiko
    Uchino, Junji
    Kimura, Hideharu
    Hiranuma, Osamu
    Chihara, Yusuke
    Tanzawa, Shigeru
    Takumi, Chieko
    Kita, Toshiyuki
    Inoue, Koji
    Minato, Koichi
    Takemoto, Shinnosuke
    Nakao, Akira
    Yoshimura, Kenichi
    Takayama, Koichi
    ONCOLOGIST, 2023, 28 (06): : 551 - +
  • [48] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Jamie E. Chaft
    Filiz Oezkan
    Mark G. Kris
    Paul A. Bunn
    Ignacio I. Wistuba
    David J. Kwiatkowski
    Dwight H. Owen
    Yan Tang
    Bruce E. Johnson
    Jay M. Lee
    Gerard Lozanski
    Maciej Pietrzak
    Michal Seweryn
    Woo Yul Byun
    Katja Schulze
    Alan Nicholas
    Ann Johnson
    Jessica Grindheim
    Stephanie Hilz
    David S. Shames
    Chris Rivard
    Eric Toloza
    Eric B. Haura
    Ciaran J. McNamee
    G. Alexander Patterson
    Saiama N. Waqar
    Valerie W. Rusch
    David P. Carbone
    Nature Medicine, 2022, 28 : 2155 - 2161
  • [49] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Chaft, Jamie E.
    Oezkan, Filiz
    Kris, Mark G.
    Bunn, Paul A.
    Wistuba, Ignacio I.
    Kwiatkowski, David J.
    Owen, Dwight H.
    Tang, Yan
    Johnson, Bruce E.
    Lee, Jay M.
    Lozanski, Gerard
    Pietrzak, Maciej
    Seweryn, Michal
    Byun, Woo Yul
    Schulze, Katja
    Nicholas, Alan
    Johnson, Ann
    Grindheim, Jessica
    Hilz, Stephanie
    Shames, David S.
    Rivard, Chris
    Toloza, Eric
    Haura, Eric B.
    McNamee, Ciaran J.
    Patterson, G. Alexander
    Waqar, Saiama N.
    Rusch, Valerie W.
    Carbone, David P.
    NATURE MEDICINE, 2022, 28 (10) : 2155 - +
  • [50] SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
    Cortes, J.
    Diab, S.
    Basho, R. K.
    Oliveira, M.
    Pluard, T.
    Alemany, C.
    Brown-Glaberman, U.
    Meisel, J.
    Boni, V.
    Sinha, R.
    Garcia Estevez, L.
    Ettl, J.
    Kuemmel, S.
    Manso Sanchez, L. M.
    Moon, Y. W.
    Villanueva Vazquez, R.
    Wuerstlein, R.
    Wang, Y.
    Wang, Z.
    Han, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S393 - S393
12345